New options in the treatment of autosomal dominant polycystic kidney disease

References

• Ecder T, Fick-Brosnahan GM, Schrier RW. Polycystic kidney disease. In: Schrier RW, ed. Diseases of the Kidney and Urinary Tract. Philadelphia: Lippincott Williams & Wilkins; 2007:502–539
   Google Scholar
• Cadnapaphornchai MA, George DM, Masoumi A, McFann K, Strain JD, Schrier RW. Effect of statin therapy on disease progression in pediatric ADPKD: Design and baseline characteristics of participants. Contemp Clin Trials. 2011;32(3):437–445
   PubMedGoogle Scholar
• Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens. 2009;18(2):99–106
   PubMed Web of Science ®Google Scholar
• Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: The last 3 years. Kidney Int. 2009;76(2):149–168
   PubMed Web of Science ®Google Scholar
• Rossetti S, Consugar MB, Chapman AB, et al. CRISP Consortium. Comprehensive molecular diagnostic in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007;18(7):2143–2160
   PubMed Web of Science ®Google Scholar
• Rappoport J. Autosomal dominant polycystic kidney disease: Pathophysiology and treatment. QJM. 2007;100(1):1–9
   PubMedGoogle Scholar
• Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006;1(1):1481–1457
   Google Scholar
• Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: Insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008;3(4):1197–1204
   PubMedGoogle Scholar
• Kazancioglu R, Ecder T, Altintepe L, et al. Turkish Society of Nephrology Polycystic Kidney Disease Working Group. Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: A multicenter experience. Nephron Clin Pract. 2011;117(3):c270–c275
   Google Scholar
• Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2013;28(2):380–385
   PubMedGoogle Scholar
• Rahbari-Oskoui F, Williams O, Chapman A. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014;29(12):2194–2201
   PubMed Web of Science ®Google Scholar
• Braun WE. Autosomal dominant polycystic kidney disease: Emerging concepts of pathogenesis and new treatments. Cleveland Clinic J Med. 2009;76(2):97–104
   PubMedGoogle Scholar
• Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003;63(2):678–685
   PubMed Web of Science ®Google Scholar
• Jafar TH, Stark PC, Schmid CH. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 2005;67(1):265–271
   PubMedGoogle Scholar
• Schrier R, McFann K, Johnson A, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002;13(7):1733–1739
   PubMed Web of Science ®Google Scholar
• Torres VE, Donovan KA, Scicli G, et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int. 1992;42:364–373
   PubMedGoogle Scholar
• McPherson EA, Luo Z, Brown RA, et al. Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2004;15:493–500
   PubMedGoogle Scholar
• Torres VE, Chapman AB, Perrone RD, et al. HALT PKD Study Group. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012;81(6):577–585
   PubMedGoogle Scholar
• Schrier RW, Abebe KZ, Perrone RD, et al. The HALT-PKD Trial Investigators. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255–2266
   PubMed Web of Science ®Google Scholar
• Torres VE, Abebe KZ, Chapman AB, et al. The HALT-PKD Trial Investigators. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2267–2276
   PubMed Web of Science ®Google Scholar
• Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nature Med. 2003;9(10):1323–1326
   PubMed Web of Science ®Google Scholar
• Ecder T, Edelstein CL, Fick-Brosnahan GM, et al. Diuretic versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol. 2001;21(2):98–103
   PubMedGoogle Scholar
• Patch C, Charlton J, Roderick PJ, Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: A population-based study. Am J Kidney Dis. 2011;57(6):856–862
   PubMed Web of Science ®Google Scholar
• Gile RD, Cowley BD Jr, Gattone VH 2nd, O'Donnell MP, Swan SK, Grantham JJ. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis. 1995;26(3):501–507
   PubMed Web of Science ®Google Scholar
• van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2001;16(11):2152–2157
   PubMed Web of Science ®Google Scholar
• Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol. 2007;293(3):F854–F859
   PubMed Web of Science ®Google Scholar
• Cadnapaphornchai MA, George DM, McFann K, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014;9(5):889–896
   PubMed Web of Science ®Google Scholar
• Wang CJ, Grantham JJ, Wetmore JB. The medicinal use of water in renal disease. Kidney Int. 2013;84(1):45–53
   PubMedGoogle Scholar
• Nagao S, Nishii K, Katsuyama M, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol. 2006;17(8):2220–2227
   PubMed Web of Science ®Google Scholar
• Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2010;5(4):693–697
   PubMed Web of Science ®Google Scholar
• Higashihara E, Nutahara K, Tanbo M, et al. Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant. 2014;29(9):1710–1719
   PubMed Web of Science ®Google Scholar
• Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1140–1150
   PubMed Web of Science ®Google Scholar
• Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ. The effect of caffeine on renal epithelial cells from patients with autosomaldominant polycystic kidney disease. J Am Soc Nephrol. 2002;13(11):2723–2729
   PubMed Web of Science ®Google Scholar
• Torres VE. Water for ADPKD? Probably, yes. J Am Soc Nephrol. 2006;17(8):2089–2091
   PubMedGoogle Scholar
• Torres VE, Sweeney WE Jr, Wang X, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int. 2003;64(5):1573–1579
   PubMed Web of Science ®Google Scholar
• Perico N, Antiga L, Caroli A, et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol. 2010;21(6):1031–1040
   PubMed Web of Science ®Google Scholar
• Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic disease (ADPKD). Nephrol Dial Transplant. 2006;21(3):598–604
   PubMed Web of Science ®Google Scholar
• Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol. 2005;16(1):46–51
   PubMed Web of Science ®Google Scholar
• Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA. 2006;103(14):5466–5471
   PubMed Web of Science ®Google Scholar
• Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol. 2008;19(3):631–638
   PubMed Web of Science ®Google Scholar
• Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):820–829
   PubMed Web of Science ®Google Scholar
• Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):830–840
   PubMed Web of Science ®Google Scholar
• Stallone G, Infante B, Grandaliano G, et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): A randomized, controlled study. Nephrol Dial Transplant. 2012;27(9):3560–3567
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68(1):206–216
   PubMed Web of Science ®Google Scholar
• Caroli A, Perico N, Perna A, et al. ALADIN study group. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial. Lancet. 2013;382(9903):1485–1495
   PubMed Web of Science ®Google Scholar
• Meijer E, Drenth JP, d'Agnolo H, et al. DIPAK Consortium. Rationale and design of the DIPAK 1 study: A randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2014;63(3):446–455
   PubMedGoogle Scholar
• Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nature Med. 2004;10(4):363–364
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Eng J Med. 2012;367(25):2407–2418
   PubMed Web of Science ®Google Scholar
• Myint TM, Rangan GK, Webster AC. Treatments to slow progression of autosomal dominant polycystic kidney disease: Systematic review and meta analysis of randomized trials. Nephrology (Carlton). 2014;19(4):217–226
   PubMed Web of Science ®Google Scholar
• Sweeney WE Jr, von Vigier RO, Frost P, Avner ED. Src inhibition ameliorates polycy stic kidney disease. J Am Soc Nephrol. 2008;19:1331–1341
   PubMed Web of Science ®Google Scholar
• Leuenroth SJ, Okuhara D, Shotwell JD, et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA. 2007;104:4389–4394
   PubMed Web of Science ®Google Scholar
• Leuenroth SJ, Bencivenga N, Chahboune H, Hyder F, Crews CM. Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD. Nephrol Dial Transplant. 2010;25:2187–2194
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Reif GA, Calvet JP, Wallace DP. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol. 2010;299(5):F944–F951
   PubMed Web of Science ®Google Scholar
• Bukanov NO, Moreno SE, Natoli TA, et al. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle. 2012;11(21):4040–4046
   PubMed Web of Science ®Google Scholar
• Fan LX, Li X, Magenheimer B, Calvet JP, Li X. Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int. 2012;81(1):76–85
   PubMed Web of Science ®Google Scholar
• Verkman AS, Synder D, Tradtrantip L, Thiagarajah JR, Anderson MO. CFTR inhibitors. Curr Pharm Des. 2013;19(19):3529–3541. Review
   PubMedGoogle Scholar
• Albaqumi M, Srivastava S, Li Z, et al. KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int. 2008;74(6):740–749
   PubMed Web of Science ®Google Scholar